Consensus document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: A North-American perspective

David P. Faxon, John W. Eikelboom, Peter B. Berger, David R. Holmes, Deepak L. Bhatt, David J. Moliterno, Richard C. Becker, Dominick J. Angiolillo

Research output: Contribution to journalArticle

186 Scopus citations

Abstract

The optimal regimen of the anticoagulant and antiplatelet therapies in patients with atrial fibrillation who have had a coronary stent is unclear. It is well recognised that "triple therapy" with aspirin, clopidogrel, and warfarin is associated with an increased risk of bleeding. National guidelines have not made specific recommendations given the lack of adequate data. In choosing the best antithrombotic options for a patient, consideration needs to be given to the risks of stroke, stent thrombosis and major bleeding. This document describes these risks, provides specific recommendations concerning vascular access, stent choice, concomitant use of proton-pump inhibitors and the use and duration of triple therapy following stent placement based upon the risk assessment.

Original languageEnglish (US)
Pages (from-to)571-584
Number of pages14
JournalThrombosis and Haemostasis
Volume106
Issue number4
DOIs
StatePublished - Oct 1 2011

Keywords

  • Antithrombotic therapy
  • Atrial fibrillation
  • Stent
  • Triple therapy
  • Warfarin

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Consensus document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: A North-American perspective'. Together they form a unique fingerprint.

  • Cite this